SANTA ANA, Calif., March 7, 2003 (PRIMEZONE) -- Wall Street Audio posts its first quarter Investor Call with Biomira Inc. (Nasdaq:BIOM) (TSX:BRA). The interview can be heard on http://www.wallstreetaudio.com.
Todd Gilligan interviews Alex McPherson, M.D., Ph.D., CEO and President of Biomira. Dr. McPherson discusses two of Biomira's drugs currently in clinical trials: THERATOPE vaccine and BLP25 Liposomal vaccine.
Dr. McPherson comments on the company's relationship with Merck KGaA of Darmstadt Germany, and discusses important upcoming clinical milestones.
Dr. McPherson also discussed the upcoming final analysis of the Company's Phase III clinical trial in metastatic breast cancer.
About Biomira
Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of vaccines containing synthetic antigens and novel strategies for cancer immunotherapy.
About Wallstreetaudio.com
Wallstreetaudio.com is an Internet portal focused on corporate disclosure. WSA produces a quarterly Investor Call with publicly traded companies which is available as a subscription service to the Company. Utilizing streaming audio technologies, WSA brings the investment community relevant and timely information on public companies who wish to provide investor's with regular access to important information. WSA is free to the public.
This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.